宫颈癌根治性放化疗联合MRI引导近距离放疗中性功能毒性的剂量学预测因素
前瞻性横断面研究纳入73例IB-IVA期宫颈癌患者,接受根治性放化疗及MRI引导近距离放疗,采用女性性功能指数和女性性困扰量表评估性毒性。73%存在性功能障碍,55%存在性困扰;多因素分析显示直肠阴道点累积剂量>65 Gy与阴道总参考空气比释动能升高与性困扰增加相关。
要点
- 宫颈癌根治性放化疗后性功能障碍和性困扰发生率高,需关注性健康结局。
- 直肠阴道点累积剂量>65 Gy与性困扰风险增加相关。
- 阴道总参考空气比释动能升高与性困扰增加相关。
核心结论
- 宫颈癌放疗后性健康是多因素问题,近距离放疗剂量学与性毒性存在新关联。
研究设计与样本
- 前瞻性横断面研究,纳入2018年8月至2022年4月73例IB-IVA期宫颈癌患者,接受根治性放化疗和MRI引导近距离放疗。
主要发现
- 性功能障碍标准(女性性功能指数≤26)达标率73%,性困扰标准(女性性困扰量表修订版≥11)达标率55%。
关键数值与推荐
- 女性性功能指数≤26定义为性功能障碍,女性性困扰量表修订版≥11定义为性困扰。
临床怎么用
- 宫颈癌近距离放疗计划中应关注直肠阴道点和阴道总参考空气比释动能,以降低性毒性风险。
- 治疗后可利用患者报告结局工具筛查性功能障碍和性困扰。
局限性
- 样本量较小(73例),为横断面设计,无法确立因果关系。
- 性毒性评估在中位19个月(范围3-63)进行,时间跨度大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Definitive radiation therapy for cervical cancer results in significant vaginal and sexual toxicity. Prior work has investigated dosimetric predictors of vaginal toxicity; however, sexual health outcomes are lacking. METHODS AND MATERIALS: Patients with stage IB to IVA cervical cancer treated with definitive chemoradiation and magnetic resonance-guided brachytherapy were enrolled in a prospective, cross-sectional study. Sexual toxicity was assessed using 2 validated patient-reported outcome measures: Female Sexual Function Index and Female Sexual Distress Scale-Revised. Clinical and treatment data were collected by chart review. Vaginal dosimetry was abstracted from individual treatment plans, including: vaginal D2cm3 (minimum dose to hottest 2 cm3 of vagina), International Commission on Radiation Units and Measurements rectovaginal point (point dose 5 mm posterior to the applicator at the top of vagina), lateral point (point dose 5 mm lateral to the applicator at the top of vagina), point dose at posterior-inferior border of the symphysis (PIBS), and PIBS ± 2 cm (point dose ± 2 cm to PIBS). Vaginal Total Reference Air Kerma assessed dose loading within the vagina. Descriptive statistics summarized the data. Correlations were evaluated using logistic and linear regression analyses. RESULTS: Between August 2018 and April 2022, 73 patients were eligible. Median age was 49 (range, 25-81), median stage was IIB, 58% had vaginal involvement at diagnosis, and 33% had vaginal involvement at brachytherapy. Patients completed patient-reported outcome measures at a median of 19 months (range, 3-63) post treatment. Criteria for sexual dysfunction and distress were met in 73% (Female Sexual Function Index ≤ 26) and 55% (Female Sexual Distress Scale-Revised ≥ 11) of participants, respectively. Cumulative International Commission on Radiation Units and Measurements rectovaginal point dose >65 Gy (odds ratio, 5.04; 95% CI, 1.18-27.99; P = .040) and Vaginal Total Reference Air Kerma (odds ratio, 1.71; 95% CI, 1.04-3.04; P = .045) were associated with increased sexual distress on multivariable analysis. CONCLUSIONS: Sexual health following radiation therapy for cervical cancer is a multifactorial issue. This analysis identifies a novel association between brachytherapy dosimetry and sexual toxicity. Further attention to and evaluation of vaginal doses could improve our understanding of sexual health outcomes.
引用
- Gulstene S, Chuk E, Conway J, et al. Dosimetric Predictors of Sexual Toxicity in Cervical Cancer Patients Treated With Definitive Chemoradiation and Magnetic Resonance Imaging-Guided Brachytherapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 41862031. doi:10.1016/j.ijrobp.2026.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。